Complement-mediated tumor cell damage induced by antibodies against membrane cofactor protein (MCP, CD46).
about
Membrane cofactor protein of the complement system: alternative splicing of serine/threonine/proline-rich exons and cytoplasmic tails produces multiple isoforms that correlate with protein phenotypeComplement and macrophage crosstalk during process of angiogenesis in tumor progressionThe Paramyxoviruses Simian Virus 5 and Mumps Virus Recruit Host Cell CD46 To Evade Complement-Mediated NeutralizationMolecular cloning of membrane cofactor protein (MCP; CD46) on B95a cell, an Epstein-Barr virus-transformed marmoset B cell line: B95a-MCP is susceptible to infection by the CAM, but not the Nagahata strain of the measles virus.Activation of the alternative complement pathway by exposure of phosphatidylethanolamine and phosphatidylserine on erythrocytes from sickle cell disease patientsHuman carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin).Surface antigen expression and complement susceptibility of differentiated neuroblastoma clones.Phospholipid-anchored and transmembrane versions of either decay-accelerating factor or membrane cofactor protein show equal efficiency in protection from complement-mediated cell damage.Mouse complement regulatory protein Crry/p65 uses the specific mechanisms of both human decay-accelerating factor and membrane cofactor proteinExpression of membrane cofactor protein (MCP, CD46) in human liver diseases.Upregulated expression of complement inhibitory proteins on bladder cancer cells and anti-MUC1 antibody immune selection.Human herpesvirus-6 entry into host cells.Diversity of sites for measles virus binding and for inactivation of complement C3b and C4b on membrane cofactor protein CD46.Targeted complement inhibition and microvasculature in transplants: a therapeutic perspective.Human herpesvirus 6 variant A but not variant B induces fusion from without in a variety of human cells through a human herpesvirus 6 entry receptor, CD46.Distribution of C3-step regulatory proteins of the complement system, CD35 (CR1), CD46 (MCP), and CD55 (DAF), in hematological malignancies.Human regulator of complement activation (RCA) gene family proteins and their relationship to microbial infection.Tumor heterogeneity and immunotherapy of cancer.Ligand binding determines whether CD46 is internalized by clathrin-coated pits or macropinocytosis.Molecular remodelling of human CD46 for xenotransplantation: designing a potent complement regulator without measles virus receptor activity.Antibody-independent classical complement pathway activation and homologous C3 deposition in xeroderma pigmentosum cell lines.Protection of human breast cancer cells from complement-mediated lysis by expression of heterologous CD59.Tumoricidal efficacy coincides with CD11c up-regulation in antigen-specific CD8(+) T cells during vaccine immunotherapy.Levels of complement regulatory proteins, CD35 (CR1), CD46 (MCP) and CD55 (DAF) in human haematological malignancies.Characterization of a glycosyl-phosphatidylinositol anchor-deficient subline of Raji cells. An analysis of the functional importance of complement inhibitors on the Raji cell line.Augmented lung adenocarcinoma cytotoxicity by the combination of a genetically modified anti-Lewis Y antibody and antibodies to complement regulatory proteins.Purification and characterization of a human membrane protein that activates the alternative complement pathway and allows the deposition of homologous complement C3.Regulation of C3 deposition on gp120 coated CD4 positive cells by decay accelerating factor and factor H.Levels of complement regulatory molecules in lung cancer: disappearance of the D17 epitope of CD55 in small-cell carcinoma.Polymorphism and proteolytic fragments of granulocyte membrane cofactor protein (MCP, CD46) of complement.Membrane cofactor protein (CD46) protects cells from complement-mediated attack by an intrinsic mechanism.CD46-utilizing adenoviruses inhibit C/EBPbeta-dependent expression of proinflammatory cytokines.Expression of CD59, a complement regulator protein and a second ligand of the CD2 molecule, and CD46 in normal and neoplastic colorectal epithelium.The CD46 transmembrane domain is required for efficient formation of measles-virus-mediated syncytiumDistribution of complement regulators (CD46, CD55 and CD59) in skin appendages, and in benign and malignant skin neoplasms.Test for ability of decay-accelerating factor (DAF, CD55) and CD59 to alleviate complement-mediated damage of xeno-erythrocytes.
P2860
Q24318004-104AC325-139F-4942-B73F-40339AB6ACD0Q26801339-78282D5A-55C9-4DF0-9E6B-49B3E12DC0B9Q27488882-DD0E0854-2B96-4D87-BF63-B202B358E104Q32101531-DED4DF7B-363D-4098-8EA8-13BD8C6C1121Q33902027-9B61FDD2-60A8-40FF-B5F8-7457B119E80FQ35782339-6480C161-587B-4EE9-8662-22B9A51B89D5Q35809851-CF54A0D8-D8DF-4311-951A-173769525EA1Q36230230-41D9A293-8B8C-4C9E-B6F9-FC75E6CD3563Q36364346-98ED06D8-A1DC-47D6-8E89-3E4B78CD3C44Q36640857-803CF050-61EF-4A4A-9067-2BBD0D340462Q37189823-6BE0CA5F-16CE-4129-9822-42C18B28FCDEQ37772887-02DA08A4-C35B-4FE4-B7AE-1D2BB5679910Q38294177-687AC407-768B-4364-A556-5DE60CD20ACAQ38592520-9DA8AE3C-6F7F-4F34-9A7E-44313258A2B8Q39683944-B9D5D440-AC9A-4AAB-89FD-780FB8B92412Q40388853-997F2BF7-41A5-4ABB-B191-2E0975AF8186Q40416090-692762C9-74E5-4B7E-87BF-E830F8665387Q40433328-9516669B-00F6-42CA-9E61-624700DEAD1CQ40637282-1E07CDEE-06DF-45D5-B0EC-221DB1E818E6Q40880051-AF58817C-1360-433A-9B20-A39D82546E1CQ40949790-FECDDF52-0A54-413D-A938-54F9D80F721CQ40975372-62BDDE45-3ED1-42E0-A6EC-5FB6749BB69CQ41073960-C506BF1D-762F-4647-B965-65323542DCBBQ41094406-2CD28835-BC0C-4DE8-8620-60DDAB6E8503Q41292337-D0BB714A-C2F6-4A7E-A936-490CED574731Q41321872-F857B117-FB06-44F5-BC36-BCE38093AC2AQ41392031-F9796937-BD82-4BB5-9EE6-260E65AE5E01Q41425849-60070313-1AB4-488F-9C68-E019121E5D5AQ41546232-1C543075-B139-4AB3-99EF-434AE913A319Q41643574-A2A83251-3C8A-4152-A8C2-EA33DEAA2CBCQ41820081-810CFE36-A88F-4EAF-A28A-E992F0A12F08Q42016952-818A2A66-DB8A-44C4-B3DC-3068FDD8267DQ42104717-E9D96FC2-79CF-4ED9-BE74-CA43DD9E1C81Q42159836-FCA7293A-AC97-4ED7-B5A7-FDBC1556C090Q42454646-173EDCB0-6C6C-4BEE-B0AC-67340FCA7809Q46215128-2C71FF63-B68C-4FB3-A33A-A326E71F9802
P2860
Complement-mediated tumor cell damage induced by antibodies against membrane cofactor protein (MCP, CD46).
description
1990 nî lūn-bûn
@nan
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
1990年论文
@zh
1990年论文
@zh-cn
name
Complement-mediated tumor cell ...... cofactor protein (MCP, CD46).
@en
type
label
Complement-mediated tumor cell ...... cofactor protein (MCP, CD46).
@en
prefLabel
Complement-mediated tumor cell ...... cofactor protein (MCP, CD46).
@en
P2093
P2860
P356
P1476
Complement-mediated tumor cell ...... cofactor protein (MCP, CD46).
@en
P2093
P2860
P304
P356
10.1084/JEM.172.6.1673
P407
P577
1990-12-01T00:00:00Z